Lymphedema Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Herantis Pharma, PureTech

March 10 07:01 2023
Lymphedema Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies - Herantis Pharma, PureTech
The Lymphedema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lymphedema pipeline products will significantly revolutionize the Lymphedema market dynamics.

DelveInsight’s “Lymphedema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Lymphedema, historical and forecasted epidemiology as well as the Lymphedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Lymphedema market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Lymphedema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lymphedema Market Insights

 

Lymphedema Overview

Lymphedema is the condition that may be caused in the body due to cancer and as a side effect of the cancer treatment. It occurs due to the buildup fluids in soft body tissues which leads to swelling in the organs, particularly limbs. Lymphedema can lead to psychological, physical and social problems in patients.

 

Some of the key facts of the Lymphedema Market Report: 

  • The Lymphedema market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In a study by Brayn C et al. (2022), Lymphedema may affect as many as 140–250 million persons worldwide. Primary lymphedema is rare, affecting 1 in 100,000 individuals. Secondary lymphedema is the most common cause of the disease and affects approximately 1 in 1000
  • In a study by Schook C et al. (2011), injury to the lymphatic system is responsible for approximately 99 % of adult cases and 3 % of pediatric disease
  • Key Lymphedema Companies: Herantis Pharma, PureTech, and others
  • Key Lymphedema Therapies: Lymfactin, LYT-100, and others
  • The Lymphedema epidemiology based on type-specific analyzed that Primary lymphedema is rare, affecting 1 in 100,000 individuals. Secondary lymphedema is the most common cause of the disease

 

Get a Free sample for the Lymphedema Market Report – 

https://www.delveinsight.com/sample-request/lymphedema-market

 

Key benefits of the Lymphedema Market report:

  1. Lymphedema market report covers a descriptive overview and comprehensive insight of the Lymphedema Epidemiology and Lymphedema market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Lymphedema market report provides insights on the current and emerging therapies.
  3. Lymphedema market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Lymphedema market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Lymphedema market.

 

Download the report to understand which factors are driving Lymphedema epidemiology trends @ Lymphedema Epidemiological Insights 

 

Lymphedema Market  

The dynamics of the Lymphedema market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“Current treatment is symptomatic and highly dependent on anti-inflammatories and pain relievers which has its own limitations. Long term usage of anti- inflammatory may result in swelling of the face, fingers, feet, or lower legs, severe stomach pain, black, tarry stools, or vomiting of blood or unusual weight gain, yellow skin or eyes.”

 

Lymphedema Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Lymphedema Epidemiology Segmentation:

The Lymphedema market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Lymphedema
  • Prevalent Cases of Lymphedema by severity
  • Gender-specific Prevalence of Lymphedema
  • Diagnosed Cases of Episodic and Chronic Lymphedema

 

Lymphedema Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lymphedema market or expected to get launched during the study period. The analysis covers Lymphedema market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Lymphedema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Lymphedema market share @ Lymphedema market forecast 

 

Lymphedema Therapies and Key Companies

  • Lymfactin: Herantis Pharma
  • LYT-100: PureTech

 

Lymphedema Market Strengths

Lymphedema is a complex disorder, efforts have been made by researchers and scientific professionals to improve the understanding of the pathogenesis and diagnosis of this condition

Treatment of Lymphedema has improved significantly in recent years with the availability of several safe and effective therapies. Several consensus guidelines have been created to further assist in the management of Lymphedema patients

 

Scope of the Lymphedema Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Lymphedema Companies: Herantis Pharma, PureTech, and others
  • Key Lymphedema Therapies: Lymfactin, LYT-100, and others
  • Lymphedema Therapeutic Assessment: Lymphedema current marketed and Lymphedema emerging therapies
  • Lymphedema Market Dynamics: Lymphedema market drivers and Lymphedema market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Lymphedema Unmet Needs, KOL’s views, Analyst’s views, Lymphedema Market Access and Reimbursement 

 

Lymphedema Market Unmet Needs

  • Challenges in diagnoses
  • Development of novel therapies
  • Limitations in gene therapy
  • Poor disease understanding
  • Clinical biomarkers

 

Table of Contents 

1. Lymphedema Market Report Introduction

2. Executive Summary for Lymphedema

3. SWOT analysis of Lymphedema

4. Lymphedema Patient Share (%) Overview at a Glance

5. Lymphedema Market Overview at a Glance

6. Lymphedema Disease Background and Overview

7. Lymphedema Epidemiology and Patient Population

8. Country-Specific Patient Population of Lymphedema 

9. Lymphedema Current Treatment and Medical Practices

10. Lymphedema Unmet Needs

11. Lymphedema Emerging Therapies

12. Lymphedema Market Outlook

13. Country-Wise Lymphedema Market Analysis (2019–2032)

14. Lymphedema Market Access and Reimbursement of Therapies

15. Lymphedema Market Drivers

16. Lymphedema Market Barriers

17.  Lymphedema Appendix

18. Lymphedema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Lymphedema treatment, visit @ Lymphedema Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

  Categories: